Low frequency of HER2 amplification and overexpression in early onset gastric cancer

Background The recent ToGA trial results indicated that trastuzumab is a new, effective, and well-tolerated treatment for HER2-positive gastric cancer (GC). Although GC mainly affects older patients, fewer than 10% of GC patients are considered early-onset (EOGC) (presenting at the age of 45 years o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cellular Oncology 2011-04, Vol.34 (2), p.89-95
Hauptverfasser:	Moelans, Cathy B., Milne, Anya N., Morsink, Folkert H., Offerhaus, G. Johan A., van Diest, Paul J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Factors Aged Aged, 80 and over Biomedical and Life Sciences Biomedicine Cancer Research Gene Amplification Gene Expression Regulation, Neoplastic Gene Frequency Humans Immunohistochemistry In Situ Hybridization, Fluorescence - methods Middle Aged Oncology Original Paper Pathology Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Stomach Neoplasms - genetics Stomach Neoplasms - metabolism Stomach Neoplasms - pathology Tissue Array Analysis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!